Pathology Office of Research Affairs Makes an Impact
Gina Della Porta, left, Director of the Office of Research Affairs, and David Stern, Professor of Pathology and Vice Chair for Basic and Translational Sciences, who oversees the office. In just one year, the Department of Pathology’s Office of Research Affairs has made an impact.
Using an IUD could significantly lower your ovarian cancer risk
From hormonal options to natural family planning, finding the right birth control method is a deeply personal decision—but luckily, you have choices. Understanding the risks and benefits of each option can help you make an informed choice that aligns with your body and lifestyle. Intrauterine devices (IUDs) are a popular choice for women who don’t want to remember to take a pill every day or are looking for a low-maintenance form of birth control. Some women love that the hormonal IUD shortens or even stops menstruation altogether. According to the American Cancer Society, nearly 20,000 women in the US will be diagnosed with ovarian cancer in 2023. “Ovarian cancer continues to be such a challenging cancer because the great majority of these cancers are still diagnosed in late stages,” shares Elena Ratner, MD, gynecologic oncologist at Yale Cancer Center.Source: Motherly
Dr. Alessandro Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer
Alessandro Santin, MD, professor, Obstetrics, Gynecology, and Reproductive Sciences, Disease Aligned Research Team Leader, Gynecologic Oncology Program, co-chief, Section of Gynecologic Oncology, Yale Cancer Center, discusses the investigation of sacituzumab govitecan-hziy (Trodelvy) in patients with recurrent endometrial carcinoma overexpressing TROP2. Investigators launched a 2-stage phase 2 clinical trial (NCT04251416) to evaluate the use of sacituzumab govitecan in this patient population. The preliminary responses from this study were presented at the 2023 ASCO Annual Meeting.Source: OncLive
Lessons from KEYNOTE-921 in Metastatic Castration Resistant Prostate Cancer
Clinical trials around the world continue to evaluate and bring promising new treatments to patients with various types of genitourinary cancers. However, not all are positive, according to Daniel P. Petrylak, MD, including the phase 3 KEYNOTE-921 study (NCT03834506).Source: Targeted Oncology
Dr Santin on the Clinical Activity of Sacituzumab Govitecan in Recurrent Endometrial Cancer
Alessandro Santin, MD, professor, Obstetrics, Gynecology, and Reproductive Sciences, Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center, co-chief, Section of Gynecologic Oncology, discusses the clinical activity of sacituzumab govitecan-hziy (Trodelvy) in patients with recurrent endometrial cancer who overexpress Trop-2. Preliminary results from stage 1 of a phase 2 trial (NCT04251416) presented at the 2023 ASCO Annual Meeting showed that among 21 patients evaluable for efficacy, the objective response rate was 33.3%, including 1 (4.8%) complete response and 6 (28.5%) partial responses. Additionally, 47.6% of patients had stable disease, and 14.3% experienced progressive disease. Notably, in 20 patients evaluable for disease control, the 6-month durable disease control rate was 35.0%.Source: OncLive
What Black Women With Ovarian Cancer Need to Know About Genetic Testing
If you are a Black American who’s already living with ovarian cancer, genetic testing may not be top of mind. But medical guidelines state that anyone diagnosed with ovarian, fallopian tube, or primary peritoneal cancer should be offered genetic testing, because it can help you make informed decisions about your cancer journey. Having genetic testing after an ovarian cancer diagnosis could actually mean saving your life, as well as the lives of both the women and men in your family. But, because Black Americans with ovarian cancer are far less likely than white Americans to get genetic testing, it’s important to have all the information and resources available to make sure everyone who needs testing has access to it. “If you don’t know your underlying genetic test results, you can’t be offered life-preserving or lifesaving therapy,” says Elena Ratner, MD, a gynecologic oncologist at Yale Cancer Center in New Haven, Connecticut.Source: Everyday Health
Yale Pathology Joins Office of Health Equity Research in Community Listening Session
Several members of Yale Pathology recently joined members of the Office of Health Equity Research (OHER) at Yale School of Medicine at a community listening session to understand how to approach people about participating in medical research.
Pei Hui, MD, Discusses New Reporting Guidelines for Gestational Trophoblastic Disease
Pei Hui, MD, PhD, Professor of Pathology and of Obstetrics, Gynecology and Reproductive Sciences, discusses updated reporting guidelines for Gestational Trophoblastic Disease.Source: International Society of Gynecologic Pathologists
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
Each year, Connecticut Magazine recognizes some of the state’s best physicians, who provide exceptional care for patients, with its annual “Top Doctors” issue. This year’s list includes 82 physicians from Smilow Cancer Hospital and Yale Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in the state.